Patents by Inventor Phillip Dan Cook
Phillip Dan Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170183373Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.Type: ApplicationFiled: March 16, 2017Publication date: June 29, 2017Applicants: MERCK SHARP & DOHME CORP., IONIS PHARMACEUTICALS, INC.Inventors: Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, David B. Olsen, Steven S. Carroll, Malcolm MacCoss
-
Publication number: 20140309412Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.Type: ApplicationFiled: June 12, 2013Publication date: October 16, 2014Inventors: Balkrishen Bhat, Anne B. El drup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
-
Patent number: 8691785Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: GrantFiled: January 7, 2013Date of Patent: April 8, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Patent number: 8481712Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.Type: GrantFiled: February 2, 2007Date of Patent: July 9, 2013Assignees: Merck Sharp & Dohme Corp., ISIS Pharmaceuticals, Inc.Inventors: Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
-
Patent number: 8377897Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: GrantFiled: September 28, 2005Date of Patent: February 19, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Publication number: 20120165515Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.Type: ApplicationFiled: February 2, 2007Publication date: June 28, 2012Inventors: Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
-
Patent number: 8153602Abstract: The present invention relates to compositions and methods for the pulmonary delivery of nucleic acids, particularly oligonucleotides. In one preferred embodiment, the compositions and methods of the invention are utilized to effect the pulmonary delivery of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic or prophylactic purposes.Type: GrantFiled: May 20, 1999Date of Patent: April 10, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Clarence Frank Bennett, David J. Ecker, Phillip Dan Cook
-
Publication number: 20110213014Abstract: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.Type: ApplicationFiled: May 13, 2011Publication date: September 1, 2011Applicant: Isis Pharmaceuticals, Inc.Inventors: Rahul C. Mehta, Gregory E. Hardee, Phillip Dan Cook, David J. Ecker, Yali Jennifer Tsai, Michael V. Templin
-
Patent number: 7964579Abstract: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.Type: GrantFiled: August 21, 2009Date of Patent: June 21, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: Rahul C. Mehta, Gregory E. Hardee, Phillip Dan Cook, David J. Ecker, Yali Jennifer Tsai, Michael V. Templin
-
Publication number: 20100311684Abstract: Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.Type: ApplicationFiled: May 10, 2010Publication date: December 9, 2010Applicant: BIOTA SCIENTIFIC MANAGEMENT PTY LTDInventors: Phillip Dan Cook, Gregory Ewing, Deborah K. Ewing, Yi Jin, John Lambert, Marija Prhavc, Vasanthankumar Rajappan, Vivek K. Rajwanshi, Kandasamy Sakthivel
-
Patent number: 7713941Abstract: Nucelosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.Type: GrantFiled: August 27, 2004Date of Patent: May 11, 2010Assignee: Biota Scientific Management Pty LtdInventors: Phillip Dan Cook, Gregory Ewing, Deborah K. Ewing, legal representative, Yi Jin, John Lambert, Marija Prhavc, Vasanthankumar Rajappan, Vivek K. Rajwanshi, Kandasamy Sakthivel
-
Publication number: 20090326045Abstract: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.Type: ApplicationFiled: August 21, 2009Publication date: December 31, 2009Applicant: Isis Pharmaceuticals, Inc.Inventors: Rahul C. Mehta, Gregory E. Hardee, Phillip Dan Cook, David J. Ecker, Yali Jennifer Tsai, Michael V. Templin
-
Publication number: 20090198047Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2?-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.Type: ApplicationFiled: June 15, 2007Publication date: August 6, 2009Applicant: Isis Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Andrew Mamoru Kawasaki
-
Publication number: 20080200423Abstract: Nucelosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.Type: ApplicationFiled: August 27, 2004Publication date: August 21, 2008Inventors: Phillip Dan Cook, Gregory Ewing, Yi Jin, John Lambert, Marija Prhavc, Vasanthankumar Rajappan, Vivek K. Rajwanshi, Kandasamy Sakthivel
-
Patent number: 7323449Abstract: The present invention provides thionucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such thionucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the thionucleoside compounds of the present invention.Type: GrantFiled: July 18, 2003Date of Patent: January 29, 2008Assignees: Merck & Co., Inc., Isis Pharmaceuticals, Inc.Inventors: David B. Olsen, Balkrishen Bhat, Phillip Dan Cook
-
Patent number: 7268119Abstract: Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.Type: GrantFiled: February 14, 2007Date of Patent: September 11, 2007Assignee: Biota Scientific Management Pty LtdInventors: Phillip Dan Cook, Deborah K. Ewing, legal representative, Yi Jin, John Lambert, Marija Prhavc, Vasanthankumar Rajappan, Vivek K. Rajwanshi, Kandasamy Sakthivel, Gregory Ewing, deceased
-
Patent number: 7235650Abstract: Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2?-position of the functionalized nucleoside via a linking group. If at least a portion of the remaining liked nucleosides are 2?-deoxy-2?-fluoro, 2?-O-methoxy, 2?-O-ethoxy, 2?-O-propoxy, 2?-O-aminoalkoxy or 2?-O-allyloxy nucleosides, the substituent can be attached via a linking group at any of the 3? or the 5? positions of the nucleoside or on the heterocyclic base of the nucleoside or on the inter-nucleotide linkage linking the nucleoside to an adjacent nucleoside.Type: GrantFiled: October 31, 2002Date of Patent: June 26, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Phillip Dan Cook, Clarence Frank Bennett
-
Patent number: 7202224Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.Type: GrantFiled: July 31, 2006Date of Patent: April 10, 2007Assignees: Merck & Co., Inc., ISIS Pharmaceuticals, Inc.Inventors: Anne B. Eldrup, Marija Prhavc, Phillip Dan Cook, Steven S. Carroll, David B. Olsen
-
Patent number: 7138517Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2?-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.Type: GrantFiled: November 28, 2001Date of Patent: November 21, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Andrew Mamoru Kawasaki
-
Patent number: RE39464Abstract: Novel chiral compounds that mimic and/or modulate the activity of wild-type nucleic acids are disclosed. In general, the compounds are phosphorothioate oligonucleotides wherein the 5?, and the 3?-terminal internucleoside linkages are chirally Sp and internal internucleoside linkages are chirally Rp.Type: GrantFiled: August 24, 2004Date of Patent: January 9, 2007Assignee: ISIS Pharmaceuticals Inc.Inventors: Phillip Dan Cook, Muthiah Manoharan